首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1356558

膀胱癌诊断市场报告：2030 年趋势、预测与竞争分析

Bladder Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日期: 2023年09月01日 | 出版商:

Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

膀胱癌诊断的趋势和预测

预计到 2030 年，全球膀胱癌诊断市场将达到 48 亿美元，2024 年至 2030 年年复合成长率为 7.8%。这个市场的主要驱动因素是人们对膀胱相关疾病的认识不断提高、老年人口不断增加，以及对电脑断层扫描和磁振造影等先进诊断技术的需求不断增加。全球膀胱癌诊断市场的未来前景广阔，医院、诊所和癌症中心市场存在商机。

膀胱癌诊断市场洞察

Lucintel 预测，有效的切片检查技术、更多地使用切片检查进行高级成像以及对经尿道膀胱肿瘤切除术的日益偏好将导致切片检查有望实现最高增长。

由于膀胱癌入院人数迅速增加以及医疗专业人员的可用性，医院可能仍然是最大的部分。

由于拥有成熟的医疗基础设施、领先的生技药品公司以及主要参与者，预计北美将在预测期内实现最高的成长。

本报告回答了 11 个关键问题：

Q.1. 细分市场中最有前途和高成长的机会是什么？
Q.2. 未来哪个细分市场成长较快？为什么？
Q.3.您认为哪些地区未来会出现更快的成长？为什么？
Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
Q.5. 这个市场的商业风险和竞争威胁是什么？
Q.6.这个市场有哪些新趋势？为什么？
Q.7.市场客户需求有何改变？
Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

宏观经济趋势（2018-2023）与预测（2024-2030）
全球膀胱癌诊断市场趋势（2018-2023）与预测（2024-2030）
按测试类型分類的全球膀胱癌诊断市场
- 尿液检查
- 膀胱镜检查
- 切片检查
- 影像检查
按癌症类型分類的全球膀胱癌诊断市场
- 膀胱移行细胞癌
- 膀胱鳞状细胞癌
- 其他的
按最终用途行业分類的全球膀胱癌诊断市场
- 医院
- 诊所
- 癌症中心
- 其他的

第4章2018-2030年分地区市场趋势及预测分析

全球膀胱癌诊断市场（按地区）
北美膀胱癌诊断市场
欧洲膀胱癌诊断市场
亚太膀胱癌诊断市场
其他区域膀胱癌诊断市场

第5章竞争分析

产品系列分析
营运整合
波特五力分析

第6章成长机会与策略分析

成长机会分析
- 按测试类型分類的全球膀胱癌诊断市场成长机会
- 全球膀胱癌诊断市场成长机会（按癌症类型）
- 全球膀胱癌诊断市场最终用途产业的成长机会
- 全球膀胱癌诊断市场区域成长机会
全球膀胱癌诊断市场新趋势
- 新产品开发
- 全球膀胱癌诊断市场的产能扩张
- 全球膀胱癌诊断市场的合併、收购与合资企业
- 认证和许可

第7章主要企业概况

Ameritech Diagnostic Reagent
Bristol-Myers Squibb
Eli Lilly
F. Hofmann-La Roche
GlaxoSmithKline
Novartis International
Pfizer
Abbott
Endo Pharmaceuticals
Johnson & Johnson

简介目录

Bladder Cancer Diagnostic Trends and Forecast

The future of the global bladder cancer diagnostic market looks promising with opportunities in the hospital, clinic, and cancer center markets. The global bladder cancer diagnostic market is expected to reach an estimated $4.8 billion by 2030 with a CAGR of 7.8% from 2024 to 2030. The major drivers for this market are growing awareness of bladder related diseases, increasing number of geriatric popuation, and rising demand for advanced diagnostic technologies like computed tomography scan and magnetic resonance imaging.

A more than 150-page report is developed to help in your business decisions.

Bladder Cancer Diagnostic by Segment

The study includes a forecast for the global bladder cancer diagnostic by test type, cancer type, end use industry, technology, and region.

Bladder Cancer Diagnostic Market by Test Type [Shipment Analysis by Value from 2018 to 2030]:

Urine Lab Tests
Cystoscopy
Biopsy
Imaging Tests

Bladder Cancer Diagnostic Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

Transitional Cell Bladder Cancer
Squamous Cell Bladder Cancer
Others

Bladder Cancer Diagnostic Market by End Use Industry [Shipment Analysis by Value from 2018 to 2030]:

Hospitals
Clinics
Cancer Centers
Others

Bladder Cancer Diagnostic Market by Region [Shipment Analysis by Value from 2018 to 2030]:

North America
Europe
Asia Pacific
The Rest of the World

List of Bladder Cancer Diagnostic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies bladder cancer diagnostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bladder cancer diagnostic companies profiled in this report include-

Ameritech Diagnostic Reagent
Bristol-Myers Squibb
Eli Lilly
F. Hofmann-La Roche
Glaxosmithkline
Novartis International
Pfizer
Abbott
Endo Pharmaceuticals
Johnson & Johnson

Bladder Cancer Diagnostic Market Insights

Lucintel forecasts that biopsy is expected to witness highest growth over the forecast period due to its substantial use for effective biopsy technique and advanced imaging and rising preference for transurethral resection of bladder tumor approach.

Hospital will remain the largest segment due to surge in bladder cancer hospitalizations and substantial availability of healthcare experts in this setting.

North America is expected to witness highest growth over the forecast period due to exisitence of well-established healthcare infrastructure, availability of major biologics companies, and presence of key players in the region.

Features of the Global Bladder Cancer Diagnostic Market

Market Size Estimates: Bladder cancer diagnostic market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Bladder cancer diagnostic market size by test type, cancer type, end use industry, and region. in terms of value ($B).

Regional Analysis: Bladder cancer diagnostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different test types, cancer typse, end use industries, and region.s for the bladder cancer diagnostic market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bladder cancer diagnostic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the bladder cancer diagnostic market size?

Answer: The global bladder cancer diagnostic market is expected to reach an estimated $4.8 billion by 2030.

Q.2. What is the growth forecast for bladder cancer diagnostic market?

Answer: The global bladder cancer diagnostic market is expected to grow with a CAGR of 7.8% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the bladder cancer diagnostic market?

Answer: The major drivers for this market are growing awareness of bladder related diseases, increasing number of geriatric popuation, and rising demand for advanced diagnostic technologies like computed tomography scan and magnetic resonance imaging.

Q.4. What are the major segments for bladder cancer diagnostic market?

Answer: The future of the bladder cancer diagnostic market looks promising with opportunities in the hospital, clinic, and cancer center markets.

Q.5. Who are the key bladder cancer diagnostic market companies?

Answer: Some of the key bladder cancer diagnostic companies are as follows:

Ameritech Diagnostic Reagent
Bristol-Myers Squibb
Eli Lilly
F. Hofmann-La Roche
GlaxoSmithKline
Novartis International
Pfizer
Abbott
Endo Pharmaceuticals
Johnson & Johnson

Q.6. Which bladder cancer diagnostic market segment will be the largest in future?

Answer: Lucintel forecasts that biopsy is expected to witness highest growth over the forecast period due to its substantial use for effective biopsy technique and advanced imaging and rising preference for transurethral resection of bladder tumor approach.

Q.7. In bladder cancer diagnostic market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to exisitence of well-established healthcare infrastructure, availability of major biologics companies, and presence of key players in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the bladder cancer diagnostic market by test type (urine lab tests, cystoscopy, biopsy, and imaging test), material (transitional cell bladder cancer, squamous cell bladder cancer, and others), end use industry (hospitals, clinics, cancer center, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

1. Executive Summary

2. Global Bladder Cancer Diagnostic Market: Market Dynamics

2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Bladder Cancer Diagnostic Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Bladder Cancer Diagnostic Market by Test Type
- 3.3.1: Urine Lab Tests
- 3.3.2: Cystoscopy
- 3.3.3: Biopsy
- 3.3.4: Imaging Tests
3.4: Global Bladder Cancer Diagnostic Market by Cancer Type
- 3.4.1: Transitional Cell Bladder Cancer
- 3.4.2: Squamous Cell Bladder Cancer
- 3.4.3: Others
3.5: Global Bladder Cancer Diagnostic Market by End Use Industry
- 3.5.1: Hospitals
- 3.5.2: Clinics
- 3.5.3: Cancer Centers
- 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

4.1: Global Bladder Cancer Diagnostic Market by Region
4.2: North American Bladder Cancer Diagnostic Market
- 4.2.1: North American Bladder Cancer Diagnostic Market by Test Type: Urine Lab Tests, Cystoscopy, Biopsy, and Imaging Tests
- 4.2.2: North American Bladder Cancer Diagnostic Market by End Use Industry: Hospitals, Clinics, Cancer Center, and Others
4.3: European Bladder Cancer Diagnostic Market
- 4.3.1: European Bladder Cancer Diagnostic Market by Test Type: Urine Lab Tests, Cystoscopy, Biopsy, and Imaging Tests
- 4.3.2: European Bladder Cancer Diagnostic Market by End Use Industry: Hospitals, Clinics, Cancer Center, and Others
4.4: APAC Bladder Cancer Diagnostic Market
- 4.4.1: APAC Bladder Cancer Diagnostic Market by Test Type: Urine Lab Tests, Cystoscopy, Biopsy, and Imaging Tests
- 4.4.2: APAC Bladder Cancer Diagnostic Market by End Use Industry: Hospitals, Clinics, Cancer Center, and Others
4.5: ROW Bladder Cancer Diagnostic Market
- 4.5.1: ROW Bladder Cancer Diagnostic Market by Test Type: Urine Lab Tests, Cystoscopy, Biopsy, and Imaging Tests
- 4.5.2: ROW Bladder Cancer Diagnostic Market by End Use Industry: Hospitals, Clinics, Cancer Center, and Others

5. Competitor Analysis

5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

6.1: Growth Opportunity Analysis
- 6.1.1: Growth Opportunities for the Global Bladder Cancer Diagnostic Market by Test Type
- 6.1.2: Growth Opportunities for the Global Bladder Cancer Diagnostic Market by Cancer Type
- 6.1.3: Growth Opportunities for the Global Bladder Cancer Diagnostic Market by End Use Industry
- 6.1.4: Growth Opportunities for the Global Bladder Cancer Diagnostic Market Region
6.2: Emerging Trends in the Global Bladder Cancer Diagnostic Market
- 6.3.1: New Product Development
- 6.3.2: Capacity Expansion of the Global Bladder Cancer Diagnostic Market
- 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Bladder Cancer Diagnostic Market
- 6.3.4: Certification and Licensing